Livanova

Considered a worldwide leader in its specialties, LivaNova operates in over 100 countries and has a workforce of about 3000 supporting its research endeavours. However it has struggled recently with lower than expected sales in some of its product lines, with fierce competition in the sector from firms such as Medtronic. Hoping to turn this around by tapping into the enthusiasm and energy of the burgeoning medtech startup sector, LivaNova has established semi-independent startups such as Epsy Health which work independently in their own specialised areas but benefit from their parent company’s marketing reach and research capabilities.

So far results from this approach have been positive, with Epsy winning CES innovation awards in 2021 and LivaNova’s share price recently increasing sharply. However, while some aspects of its business are currently suffering, the company is moving to divest itself of unprofitable areas and doubling down on its rapidly growing cardiopulmonary and neuromodulation divisions. It will also continue to form partnerships with medtech companies such as Teguar, bringing fresh innovations to its global client base and improvements to their patients’ quality of life worldwide.